EPM
BMY.RT

Equitec Proprietary Markets’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Equitec Proprietary Markets’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$7K Sell
10,100
-6,800
-40% -$14.5K ﹤0.01% 112
2020
Q3 		$38K Buy
+16,900
New +$48.3K 0.03% 72

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BFS
Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return
LGP
Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Equitec Proprietary Markets's BMY.RT Position: Q4 2020 in Review

Equitec Proprietary Markets reduced its Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) stake by 40% in Q4 2020, selling an estimated $14.5K and leaving 10,100 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #112.

Equitec Proprietary Markets first reported a position in BMY.RT in Q3 2020 and has held it in 2 quarters since. The position peaked at $38K in Q3 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Equitec Proprietary Markets held 10,100 shares of Bristol-Myers Squibb Company Contingent Value Rights worth $7K as of Q4 2020.
  • Equitec Proprietary Markets sold 6,800 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $14.5K.
  • Bristol-Myers Squibb Company Contingent Value Rights made up ﹤0.01% of Equitec Proprietary Markets's portfolio in Q4 2020, its #112 holding.
  • Equitec Proprietary Markets first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q3 2020 and has held it in 2 quarters since.
  • Equitec Proprietary Markets's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $38K in Q3 2020.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Equitec Proprietary Markets's 13F filing for Q4 2020, filed 26 Jan 2021.